Recent research reports have been published by other analysts about the stock. Oppenheimer reduced their target price for shares of Sarepta Therapeutics, from $180.00 down to $150.00. They also set an outperform ratings on the stock. This was in a report published on Thursday 9th March. Robert W. Baird raised their price target for Sarepta Therapeutics to $202.00 in a research report on March 1st. Barclays raised their price target on Sarepta Therapeutics in a Friday research report from $170.00 up to $193.00. Citigroup began covering shares of Sarepta Therapeutics on Tuesday, 4th April in a research note. The stock was given a buy recommendation and a price target of $179.00. In a research report published on Friday, 14th April, Mizuho reiterated its buy rating on Sarepta Therapeutics and set a price target of $160.00. Two analysts gave the stock a hold recommendation, and fourteen others have given the stock a buy recommendation. The stock opened Friday at $114.09. The company's 50-day moving average of $129.38, and its 200 day moving average of $129.55. The company's quick ratio is 4.26, its current ratio is 4.63, and it has a debt to equity ratio of 1.73. The company has a $10.63 billion market cap, a PE of -8.99, and a beta value of 1.01. Sarepta Therapeutics' 52-week low is $70.32 while its 52-week high is $159.89.
The last time ) announced its quarterly results was on May 2nd. The biotechnology firm reported ($0.97) in earnings per share for the quarter. This was $0.49 higher than analysts' expectations of ($1.46). Revenue for the quarter was $253.50 millions, which is higher than the $241.47-million consensus estimate. Sarepta Therapeutics's negative net margin was 114.30%, and its negative return on equity was 128.64%. Revenue was up by 20.2% from the same quarter of last year. In the same quarter of last year, Sarepta Therapeutics earned ($1.20). Analysts expect Sarepta Therapeutics to post -10.9 earnings a share in the current year.
Sarepta Therapeutics Institutional Trading
Recently, hedge funds and institutional investors bought and sold shares in the company. KB Financial Partners LLC purchased a new position of shares in Sarepta Therapeutics worth approximately $36,000 during the first quarter. FourThought Financial LLC increased its stake in Sarepta Therapeutics during the third quarter by 43.5%. FourThought Financial LLC owns now 297 shares worth $33,000 of the stock of the biotechnology firm after buying an additional 90 during the last quarterly. Armstrong Advisory Group Inc. purchased a new Sarepta Therapeutics position during the fourth quarter, valued at about $39,000. Harvest Fund Management Co. Ltd bought a new Sarepta Therapeutics position in the first-quarter valued at around $49,000. Clearstead Advisors LLC also acquired a stake in Sarepta Therapeutics worth $49,000 during the first quarter. Currently, 85.59% is owned by hedge funds and institutional investors.
Sarepta Therapeutics, Inc., a biopharmaceutical commercial-stage company, focuses its efforts on the development and discovery of RNA-targeted therapies, gene therapy, and other genetic treatment modalities to treat rare diseases. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment rare diseases.
MarketBeat.com offers a FREE daily email newsletter